Lamininα1, Novel cancer embryonal antigen of renal cell carcinoma

• Project/Area Number: 21592050
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Urology
• Research Institution: Kochi University
• Principal Investigator: KARASHIMA Takashi 高知大学, 教育研究部・医療学系, 助教 (60304672)
• Co-Investigator(Kenkyū-buntansha): INOUE Keiji 高知大学, 教育研究部・医療学系, 准教授 (00294827) ; SHUIN Taro 高知大学, 教育研究部・医療学系, 教授 (70128601)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: ラミニンα1 / 腎細胞癌 / 癌胎児性抗原 / 癌胎児性抗体

Research Abstract

We have demonstrated that the missense mutation of von Hippel-Lindau tumor suppresser gene affected highly expression of lamininα1 leading to increase tumorigenisity in human renal cell carcinoma(RCC). We investigated function of lamininα1 and determined whether lamininα1 would be novel tumor maker and target molecule in human RCC. Highly expression of integrinα4 was identified in the human RCC cell expressing lamininα1. The therapy with anti-lamininα1 antibody and shRNA suppressed tumor growth of the RCC cell expressing lamininα1. However, lamininα1 was not stably detected in the serum or the urine of mice bearing human RCC. In conclusions, lamininα1 is novel target molecule in human RCC. Lamininα1 may affect tumorigenisity via integrinα4.

Research Products

• [Journal Article] Adjuvants determine the contribution of basophils to antigen sensitization in vivo (2011)
  • Author(s): Ishida W, Fukuda K, Sumi T, Ebihara N, Kaiisako M, Matsuda H, Yagita H, Fukushima A
  • Journal Title: Immunol Lett Volume: 136 Pages: 49-54
  • Peer Reviewed